RIGL · Rigel Pharmaceuticals Inc
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-08 | HANNAH ALISON L. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027. Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended. |
Common Stock
|
24,400 |
| 2026-06-22 | Ali-Jackson Kamil |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes. |
Common Stock
|
2,500 |
| 2026-06-17 | Schorno Dean L |
EVP & Chief Financial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. |
Employee Stock Option (right to buy)
|
7,394 |
| 2026-06-17 | Rojkjaer Lisa |
EVP, Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on March 27, 2024, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $14.90, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. |
Employee Stock Option (right to buy)
|
9,375 |
| 2026-06-17 | Rojkjaer Lisa |
EVP, Chief Medical Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. |
Employee Stock Option (right to buy)
|
7,394 |
| 2026-06-17 | Santos David A |
EVP, Chief Commercial Officer |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. |
Employee Stock Option (right to buy)
|
7,394 |
| 2026-06-17 | RODRIGUEZ RAUL R |
Director, CEO, President |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. |
Employee Stock Option (right to buy)
|
31,700 |
| 2026-06-17 | Furey Raymond J. |
EVP, GC, CCO & Corp Sec |
Award↑
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. |
Employee Stock Option (right to buy)
|
7,394 |
| 2026-06-01 | Schorno Dean L |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period. |
Employee Stock Option (right to buy)
|
2,181 |
| 2026-06-01 | RODRIGUEZ RAUL R |
Director, CEO, President |
Tax↓
|
Common Stock
|
2,424 |
| 2026-06-01 | Schorno Dean L |
EVP & Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. |
Common Stock
|
2,181 |
| 2026-06-01 | Schorno Dean L |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer through each such period. |
Employee Stock Option (right to buy)
|
1,200 |
| 2026-06-01 | Schorno Dean L |
EVP & Chief Financial Officer |
Convert↑
|
Common Stock
|
1,200 |
| 2026-06-01 | Furey Raymond J. |
EVP, GC, CCO & Corp Sec |
Tax↓
|
Common Stock
|
877 |
| 2026-06-01 | Schorno Dean L |
EVP & Chief Financial Officer |
Tax↓
|
Common Stock
|
928 |
| 2026-06-01 | Santos David A |
EVP, Chief Commercial Officer |
Tax↓
|
Common Stock
|
874 |
| 2026-06-01 | Rojkjaer Lisa |
EVP, Chief Medical Officer |
Tax↓
|
Common Stock
|
850 |
| 2026-05-26 | Ali-Jackson Kamil |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. |
Common Stock
|
2,500 |
| 2026-05-15 | MILLER MICHAEL PATRICK |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Common Stock
|
5,750 |
| 2026-05-15 | MOOS WALTER H |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Common Stock
|
5,750 |
| 2026-05-15 | HANNAH ALISON L. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Common Stock
|
5,750 |
| 2026-05-15 | Frohlich Mark W |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Common Stock
|
5,750 |
| 2026-05-15 | Ali-Jackson Kamil |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Common Stock
|
5,750 |
| 2026-05-15 | Wasman Jane |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Common Stock
|
5,750 |
| 2026-05-15 | LAPOINTE ANTHONY GREGG |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Common Stock
|
5,750 |
| 2026-02-20 | MOOS WALTER H |
Director |
Convert↑
Filing footnotes — Common Stock (Direct)
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. |
Common Stock
|
4,000 |
| 2026-02-20 | MOOS WALTER H |
Director |
Sell↓
|
Common Stock
|
4,000 |
| 2026-02-20 | MOOS WALTER H |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. The shares vested monthly over twelve (12) months from the grant date of May 11, 2016. |
Stock Option (right to buy)
|
4,000 |
| 2026-02-17 | Schorno Dean L |
EVP & Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. |
Common Stock
|
20,636 |
| 2026-02-17 | Santos David A |
EVP, Chief Commercial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. |
Common Stock
|
19,430 |
| 2026-02-17 | RODRIGUEZ RAUL R |
Director, CEO, President |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. |
Common Stock
|
53,915 |
| 2026-02-17 | Rojkjaer Lisa |
EVP, Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. |
Common Stock
|
18,894 |
| 2026-02-17 | Furey Raymond J. |
EVP, GC, CCO & Corp Sec |
Award↑
Filing footnotes — Common Stock (Direct)
The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. |
Common Stock
|
19,497 |
| 2026-02-10 | Schorno Dean L |
EVP & Chief Financial Officer |
Tax↓
|
Common Stock
|
3,546 |
| 2026-02-10 | RODRIGUEZ RAUL R |
Director, CEO, President |
Tax↓
|
Common Stock
|
7,607 |
| 2026-02-10 | Rojkjaer Lisa |
EVP, Chief Medical Officer |
Tax↓
|
Common Stock
|
3,758 |
| 2026-02-10 | Furey Raymond J. |
EVP, GC, CCO & Corp Sec |
Tax↓
|
Common Stock
|
3,546 |
| 2026-02-10 | Santos David A |
EVP, Chief Commercial Officer |
Tax↓
|
Common Stock
|
3,546 |
| 2026-02-02 | RODRIGUEZ RAUL R |
Director, CEO, President |
Tax↓
|
Common Stock
|
14,110 |
| 2026-02-02 | Santos David A |
EVP, Chief Commercial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Includes 1,000 shares acquired under the Issuer's stock purchase plan. |
Common Stock
|
5,718 |
| 2026-02-02 | Furey Raymond J. |
EVP, GC, CCO & Corp Sec |
Tax↓
Filing footnotes — Common Stock (Direct)
Includes 1,000 shares acquired under the Issuer's stock purchase plan. |
Common Stock
|
3,968 |
| 2026-02-02 | Schorno Dean L |
EVP & Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Includes 500 shares acquired under the Issuer's stock purchase plan. |
Common Stock
|
5,488 |
| 2026-02-01 | MILLER MICHAEL PATRICK |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option shall vest in equal monthly installments over a period beginning on February 1, 2026 and ending on the date of the annual meeting at which the Reporting Person is first scheduled to be considered for election by the stockholders, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Stock Option (right to buy)
|
12,000 |
| 2026-01-26 | RODRIGUEZ RAUL R |
Director, CEO, President |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. |
Employee Stock Option (right to buy)
|
40,000 |
| 2026-01-26 | RODRIGUEZ RAUL R |
Director, CEO, President |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. The shares vested monthly over two (2) years from January 1, 2016. |
Employee Stock Option (right to buy)
|
40,000 |
| 2026-01-26 | RODRIGUEZ RAUL R |
Director, CEO, President |
Convert↑
Filing footnotes — Common Stock (Direct)
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Includes 1,000 shares acquired under the Issuer's stock purchase plan. |
Common Stock
|
40,000 |
| 2026-01-26 | RODRIGUEZ RAUL R |
Director, CEO, President |
Convert↑
Filing footnotes — Common Stock (Direct)
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. |
Common Stock
|
40,000 |
| 2026-01-26 | RODRIGUEZ RAUL R |
Director, CEO, President |
Tax↓
|
Common Stock
|
35,424 |
| 2026-01-26 | RODRIGUEZ RAUL R |
Director, CEO, President |
Tax↓
|
Common Stock
|
35,211 |
| 2025-12-22 | Schorno Dean L |
EVP & Chief Financial Officer |
Convert↓
Filing footnotes — Employee Stock Option (right to buy) (Direct)
These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. The shares of common stock subject to the option vested in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019, subject to the reporting person's continuous service to the Issuer through each such period. |
Employee Stock Option (right to buy)
|
1,987 |